BCLI

Brainstorm Cell Therapeutics Inc

Add to Watchlist

Advanced Chart

0.975

+0.055(+5.980%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.000

Open

0.920

VWAP

0.95

Vol

186.05K

Mkt Cap

6.36M

Low

0.900

Amount

177.43K

EV/EBITDA(TTM)

Total Shares

68.34M

6.17M

EV/OCF(TTM)

P/S(TTM)

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimers disease (AD) and other neurodegenerative diseases. NurOwn, the Company’s cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its Phase III ALS and Phase II PMS clinical trials. Its wholly owned Israeli subsidiary, BrainStorm Cell Therapeutics Ltd., holds rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd. and two others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

FY2025Q2

-0.270

-82%

-0.440

-26.67%

Estimates Revision

The market is revising No Change the revenue expectations for Brainstorm Cell Therapeutics Inc. (BCLI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -51.01%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-51.01%

In Past 3 Month

1 Analyst Rating

515.38% Upside

Wall Street analysts forecast BCLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCLI is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

515.38% Upside

Current: 0.975

Low

6.00

Averages

6.00

High

6.00

515.38% Upside

Current: 0.975

Low

6.00

Averages

6.00

High

6.00

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

2024-07-11

Reason

Maxim Group

Jason McCarthy

Price Target

2024-07-11

Upgrades

Hold

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Brainstorm Cell Therapeutics Inc (BCLI.O) is -0.44, compared to its 5-year average forward P/E of -4.66. For a more detailed relative valuation and DCF analysis to assess Brainstorm Cell Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.66

Current PE

-0.44

Overvalued PE

-1.23

Undervalued PE

-8.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.35

Current EV/EBITDA

-0.46

Overvalued EV/EBITDA

0.35

Undervalued EV/EBITDA

-1.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.20

Current PS

0.00

Overvalued PS

16.22

Undervalued PS

-5.82